Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-1-22
pubmed:abstractText
The first tissue-specific angiogenic molecule, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was identified recently in human ovary, raising hopes of developing tumor type-specific angiogenesis inhibitors. In the present study, we analyzed the expression of EG-VEGF mRNA in normal human tissues and ovarian neoplasms by quantitative real-time reverse transcription-PCR. EG-VEGF mRNA was expressed in all ovarian neoplasms examined. No significant difference was identified among benign, low malignant potential neoplasms or stage I ovarian cancer, all of which exhibited 2-fold lower mRNA levels compared with normal premenopausal ovaries. EG-VEGF mRNA levels further decreased in late stage compared with early stage carcinomas (P < 0.05) and were consistently lower in laser capture microdissected tumor islets compared with surrounding stroma. EG-VEGF was undetectable by reverse transcription-PCR in 17 established epithelial ovarian cancer cell lines or in cultured human ovarian surface epithelial cells, whereas it was detected in peripheral blood as well as tumor-infiltrating T lymphocytes. Finally, in contrast to VEGF, EG-VEGF mRNA levels did not correlate with clinical outcome in advanced ovarian carcinoma. These results suggest that EG-VEGF is most likely derived from nonepithelial components of ovarian carcinomas and may play a marginal role in promoting angiogenesis in advanced ovarian carcinoma. We postulate that EG-VEGF-targeted antiangiogenic therapy may prove useful in early stage but not in advanced stage ovarian carcinoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
264-72
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12538479-Angiogenesis Inducing Agents, pubmed-meshheading:12538479-Carcinoma, pubmed-meshheading:12538479-Endocrine Glands, pubmed-meshheading:12538479-Endothelial Growth Factors, pubmed-meshheading:12538479-Female, pubmed-meshheading:12538479-Flow Cytometry, pubmed-meshheading:12538479-Gastrointestinal Hormones, pubmed-meshheading:12538479-Humans, pubmed-meshheading:12538479-Immunohistochemistry, pubmed-meshheading:12538479-Intercellular Signaling Peptides and Proteins, pubmed-meshheading:12538479-Lasers, pubmed-meshheading:12538479-Lymphokines, pubmed-meshheading:12538479-Microscopy, Fluorescence, pubmed-meshheading:12538479-Ovarian Neoplasms, pubmed-meshheading:12538479-RNA, Messenger, pubmed-meshheading:12538479-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:12538479-Time Factors, pubmed-meshheading:12538479-Tissue Distribution, pubmed-meshheading:12538479-Treatment Outcome, pubmed-meshheading:12538479-Tumor Cells, Cultured, pubmed-meshheading:12538479-Vascular Endothelial Growth Factor, Endocrine-Gland-Derived, pubmed-meshheading:12538479-Vascular Endothelial Growth Factor A, pubmed-meshheading:12538479-Vascular Endothelial Growth Factors
pubmed:year
2003
pubmed:articleTitle
Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.
pubmed:affiliation
Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't